Tag:
fidaxomicin
Latest Headlines
Latest Headlines
Optimer inks $90M C. difficile drug pact with Astellas
Optimer is pocketing a $20 million up-front payment on a new commercial pact for its treatment for C. difficile.
Stage set for Optimer's weapon against deadly infections
As we put this edition of FierceBiotech to bed, there was still no word from the FDA on potential approval of Optimer Pharmaceuticals' antibiotic fidaxomicin (Dificid). The PDUFA date of May 30 falls
Optimer readies antibiotic campaign after winning FDA panel vote
Optimer Pharmaceuticals won the unanimous support of an FDA panel of experts for its new antibiotic fidaxomicin and can now march into the agency with a solid endorsement on safety and efficacy. But
FDA panel readies pivotal review of Optimer's fidaxomicin
Optimer Pharmaceuticals is going into today's expert panel meeting on the antibiotic fidaxomicin armed with some positive remarks from regulators and high hopes for what could become its first
Ahead of panel, FDA staffers back Optimer's antibiotic fidaxomicin
In advance of Tuesday's expert panel review, FDA staffers say they agree with Optimer Pharmaceutical's results from two late-stage studies of its experimental antibiotic. The drug, called
